NEW YORK (GenomeWeb) — Bio-Rad said after the close of the market on Tuesday that its first quarter revenues increased 2 percent as its Life Science sales spiked 3 percent year over year.

The company also disclosed that its acquisition of sequencing technology developer GnuBio, announced earlier this year, is worth up to $110 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.